Ocular Therapeutix (OCUL) Capital Expenditures (2013 - 2026)

Ocular Therapeutix's Capital Expenditures history runs 14 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 31.35% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $11.4 million, a 533.91% increase from a year earlier, with the FY2025 full-year figure at $12.0 million, up 9825.62% from the prior year.
• Capital Expenditures declined to $1.3 million in Q1 2026 per OCUL's latest filing, from $2.8 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $6.0 million in Q3 2025 and bottomed at -$5.1 million in Q3 2023.
• The 5-year median for Capital Expenditures is $907000.0 (2022), against an average of $1.2 million.
• Across the five-year window, Capital Expenditures slumped 2299.14% in 2023 and jumped 18060.61% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $907000.0 in 2022, then surged by 541.68% to $5.8 million in 2023, then sank by 99.23% to $45000.0 in 2024, then surged by 6208.89% to $2.8 million in 2025, then slumped by 53.26% to $1.3 million in 2026.
• Per Business Quant, the three latest OCUL Capital Expenditures figures stand at $1.3 million (Q1 2026), $2.8 million (Q4 2025), and $6.0 million (Q3 2025).